Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting

Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting

Robust enrollment of 173 patients across dose escalation and expansion cohorts, with objective responses observed across five tumor types

JK06 continued to demonstrate a highly differentiated MMAE safety profile with predominantly low-grade, manageable treatment-related adverse events (TRAEs) at doses selected for expansion cohorts

Objective response rate (ORR) of 50% (5 of 10) among response-evaluable squamous non-small cell lung cancer (NSCLC) patients treated at the 4.5 mg/kg dose; overall disease control rate (DCR) of 94% (16 of 17) across all response-evaluable squamous NSCLC patients

Durable anti-tumor activity also observed in non-squamous and EGFR-mutant NSCLC, multiple breast cancer subtypes, and additional 5T4-expressing solid tumors